骨科生物制剂研究最低信息要求(MIBO):富血小板血浆与间充质干细胞
该研究采用德尔菲共识法,为评估富血小板血浆(PRP)和间充质干细胞(MSCs)的临床研究制定最低报告要求。PRP组23名专家经3轮调查后58个条目达成共识,汇编为23条清单;MSCs组23名专家经3轮调查后61个条目达成共识,汇编为25条清单。这些清单规定了评估PRP或MSCs的临床研究应报告的最低信息。
要点
- PRP研究最低报告清单包含23条声明,由58个共识条目汇编而成。
- MSCs研究最低报告清单包含25条声明,由61个共识条目汇编而成。
- 共识定义为>75%同意且<5%不同意,PRP和MSCs专家各24人受邀、各23人(96%)完成3轮调查。
核心结论
- 本研究通过专家共识确立了评估PRP和MSCs的临床研究的最低报告要求。
- 这些清单为评估PRP或MSCs的临床研究应报告的最低信息提供了规范。
研究设计与样本
- 采用德尔菲共识方法,由工作组促进制定PRP和MSCs两份专家共识声明。
- PRP和MSC专家组成员各由AAOS和AOSSM研讨会的24名受邀讲者组成,各进行3轮调查。
- 通过检索已发表文献和方案生成可报告条目的详尽列表,每轮调查后使用预设标准精简条目列表。
主要发现
- PRP方面,从文献中识别出93个实验性信息条目,23名专家(96%)完成3轮调查,58个条目达成共识(>75%同意且<5%不同意),汇编为23条清单。
- MSCs方面,从已发表文献中识别出103个条目,23名专家(96%)完成3轮调查,61个条目达成共识,汇编为25条清单。
关键数值与推荐
- PRP清单:23条声明,基于58个共识条目,共识标准为>75%同意且<5%不同意。
- MSCs清单:25条声明,基于61个共识条目。
临床怎么用
- 这些清单为评估PRP或MSCs的临床研究应报告的最低信息提供了规范。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A comprehensive approach to the evaluation of biologic therapies for musculoskeletal conditions is required to guide appropriate future use. Clinical studies evaluating platelet-rich plasma (PRP) and mesenchymal stem cells (MSCs) are limited by inadequate reporting of scientific details critical to outcome. We developed minimum reporting requirements for clinical studies evaluating PRP and MSCs using Delphi consensus methods. METHODS: The need for consensus on the minimum reporting requirements for studies evaluating biologics was identified at the American Academy of Orthopaedic Surgeons/Orthopaedic Research Society (AAOS/ORS) Biologic Treatments for Orthopaedic Injuries Symposium in 2015 and the American Orthopaedic Society for Sports Medicine (AOSSM) Biologic Treatments for Sports Injuries II Think Tank in 2015. A working group facilitated the development of 2 expert consensus statements for PRP and MSCs using Delphi techniques. Exhaustive lists of items that could be reported on by clinical studies evaluating PRP or MSCs were generated by searching the published literature and protocols. PRP and MSC expert groups, each made up of 24 invited speakers at the AAOS and AOSSM symposia, were surveyed on 3 occasions to establish consensus on the inclusion of each item within minimum reporting guidelines. In addition to rating their agreement, the experts were encouraged to propose further items or modifications. Predefined criteria were used to refine item lists after each survey. Final lists were compiled into checklist statements by the working group. RESULTS: For PRP, the working group identified 93 experimental information items from the literature. Twenty-three experts (96%) completed 3 rounds of surveys. After 3 rounds, 58 items generated consensus with >75% agreement and <5% disagreement. These items were compiled into a 23-statement checklist. For MSCs, 103 items were identified from the published literature. Twenty-three experts (96%) completed 3 rounds of surveys. After 3 rounds, the 61 items for which consensus was reached were compiled into a 25-statement checklist. CONCLUSIONS: This study has established expert consensus on the minimum reporting requirements for clinical studies evaluating PRP and MSCs. CLINICAL RELEVANCE: These checklists provide specifications for the minimum information that should be reported by clinical studies evaluating PRP or MSCs.
引用
- Murray IR, Geeslin AG, Goudie EB, et al. Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO): Platelet-Rich Plasma and Mesenchymal Stem Cells. J Bone Joint Surg Am. 2017. PMID: 28509821. doi:10.2106/JBJS.16.00793
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。